Biofrontera Inc. to Report First Quarter Financial Results on May 13, 2022
Biofrontera Inc. (Nasdaq: BFRI) will announce its financial results for Q1 2022 on May 13, 2022, prior to U.S. market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Biofrontera Inc. (Nasdaq: BFRI) will announce its financial results for Q1 2022 on May 13, 2022, prior to U.S. market opening. A conference call is scheduled for the same day at 11:00 a.m. ET to discuss the results and provide a business update. The company specializes in dermatological treatments, focusing on photodynamic therapy and topical antibiotics. Its licensed products treat actinic keratoses and impetigo.
Positive
- Scheduled conference call for May 13, 2022, indicating planned transparency with investors.
Negative
- None.
Details
News Market Reaction – BFRI
The recorded move for BFRI in the trading session of this news was -3.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WOBURN, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial results for the three months ended March 31, 2022 before the opening of the U.S. financial markets on Friday, May 13, 2022 and will hold a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.
Conference Call and Webcast Information
| Event: | Biofrontera Inc. First Quarter 2022 Financial Results and Business Update Conference Call |
| Date: | Friday, May 13, 2022 |
| Time: | 11:00 a.m. Eastern time |
| Conference call: | 1-877-877-1275 (U.S.) 1-412-858-5202 (international) |
| Webcast: | Live and 90-day replay webcast are available here and at www.investors.biofrontera-us.com. |
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.
Contacts
Biofrontera Inc.
Anke zur Mühlen
+1 781 486 1539
us-ir@biofrontera.com
LHA Investor Relations
Tirth T. Patel
+1 212 201 6614
tpatel@lhai.com
# # #
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.